TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22429452

Group type: EXPERIMENTAL
Intervention: Pathological gamblers
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 20862940

Group type: EXPERIMENTAL
Intervention: Shallow needling combined with acupoint application on top of routine medication.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine medication (control group).
Number of subjects: 120
Study: 19049703

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg twice daily + bicarbonate hydration
Number of subjects: 60
Study: 15709658

Group type: EXPERIMENTAL
Intervention: Thought Translation Device (TTD) with integrated Detection of Cognitive Activity (DCA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study: 14734261

Group type: EXPERIMENTAL
Intervention: 8-week behavior modification program
Number of subjects: 184

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 184
Study: 10889804

Group type: EXPERIMENTAL
Intervention: Intensive diet-exercise programme
Number of subjects: 523

Group type: COMPARATOR
Intervention: General information about weight reduction, physical activity and healthy diet
Number of subjects: 523
Study: 9364366

Group type: EXPERIMENTAL
Intervention: Intermittent testosterone enanthate treatment (25‐100 mg every two weeks for three months)
Number of subjects: 22
Study: 1467514

Group type: EXPERIMENTAL
Intervention: BCR-ABL positive group
Number of subjects: 56

Group type: COMPARATOR
Intervention: BCR-ABL negative group
Number of subjects: 56
Study: 3971528

Group type: EXPERIMENTAL
Intervention: Incremental low-energy protocol from 0.03 to 2.2 J (group A, 11 patients)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Incremental high-energy protocol from 0.5 to 10.0 J (group B, 11 patients)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (drug-free state)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Overall efficacy of transvenous cardioversion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Successful transvenous cardioversion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Transient arrhythmias after cardioversion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Acceleration of VT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Termination of shock protocols due to acceleration of VT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Displacement of electrode catheters after transvenous cardioversion
Number of subjects: 22
Study: 31121375

Group type: EXPERIMENTAL
Intervention: Hemostatic gelatin sponge impregnated with ropivacaine 0.5%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline NaCl 0.9%
Number of subjects: 30
Study: 29516990

Group type: EXPERIMENTAL
Intervention: Thalidomide 150 mg/day and cinobufagin 2700 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cinobufagin 2700 mg/day (Control)
Number of subjects: 54
Study: 26849844

Group type: EXPERIMENTAL
Intervention: SEP-432 (300 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 25391194

Group type: EXPERIMENTAL
Intervention: 5 mg folic acid for 2 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 50
Study: 22227760

Group type: EXPERIMENTAL
Intervention: Peer-run course 'Recovery Is Up to You' for 12 weeks
Number of subjects: 333

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 333
Study: 20131040

Group type: EXPERIMENTAL
Intervention: Acupuncture in the non-anesthesia area (NAA) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Anesthesia area (AA) group
Number of subjects: 60
Study: 18455727

Group type: EXPERIMENTAL
Intervention: Active pill phase (oral contraceptives)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Early follicular phase (naturally cycling women)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Midluteal phase (naturally cycling women)
Number of subjects: 36
Study: 15932917

Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: COMPARATOR
Intervention: PCOS patients without metformin therapy
Number of subjects: 28
Study: 12940609

Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg) and dipyridamole (5 mg/kg) for 1 year
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dipyridamole (5 mg/kg) only for 1 year
Number of subjects: 30
Study: 10395628

Group type: EXPERIMENTAL
Intervention: Live-culture yogurt (200 g/d for 1 year)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pasteurized yogurt (200 g/d for 1 year)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no yogurt)
Number of subjects: 0
Study: 8734343

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 1763597

Group type: EXPERIMENTAL
Intervention: Heparin injection
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 10
Study: 6507426

Group type: EXPERIMENTAL
Intervention: Rising socioeconomic status in Mexican American women
Number of subjects: 2217

Group type: EXPERIMENTAL
Intervention: Rising socioeconomic status in Mexican American men
Number of subjects: 2217

Group type: COMPARATOR
Intervention: Comparison of diabetes prevalence
Number of subjects: 2217

Group type: COMPARATOR
Intervention: Comparison of 'obesity-related' risk factors
Number of subjects: 2217
Study: 31556652

Group type: EXPERIMENTAL
Intervention: Therapist-guided online F-PST (n = 56)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Self-guided online F-PST (n = 60)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Face-to-face F-PST (n = 34)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Parent-proxy HBI ratings
Number of subjects: 150
Study: 30169462

Group type: EXPERIMENTAL
Intervention: Hygiene information and advice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valaciclovir 8 g daily
Number of subjects: 0
Study: 27249781

Group type: EXPERIMENTAL
Intervention: 100 μg LSD
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 200 μg LSD
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24286542

Group type: EXPERIMENTAL
Intervention: Ear acupressure on four designated acupressure points on both ears
Number of subjects: 256

Group type: COMPARATOR
Intervention: Tapes on four irrelevant points (Control)
Number of subjects: 256
Study: 22326464

Group type: EXPERIMENTAL
Intervention: 1000 mg of methylprednisolone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 20857371

Group type: EXPERIMENTAL
Intervention: Activated NG‐Shield device
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonactive NG‐Shield device
Number of subjects: 24
Study: 23057605

Group type: EXPERIMENTAL
Intervention: Permissive underfeeding (50% of calculated caloric requirement)
Number of subjects: 862

Group type: COMPARATOR
Intervention: Target feeding (100% of calculated caloric requirement)
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: Permissive underfeeding
Number of subjects: 862

Group type: COMPARATOR
Intervention: Target feeding
Number of subjects: 862
Study: 15936423

Group type: EXPERIMENTAL
Intervention: Corticosteroids (methylprednisolone) administered via a 48-hour infusion
Number of subjects: 10008

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10008
Study: 12007755

Group type: EXPERIMENTAL
Intervention: PRO‐SELF Copyright Pain Control Program
Number of subjects: 85

Group type: COMPARATOR
Intervention: Provision of information about cancer pain management
Number of subjects: 85
Study: 10473926

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single dose)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Cefoxitin (3 times a day for 3 days)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 195

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 195
Study: 8712912

Group type: EXPERIMENTAL
Intervention: Lateral laparoscopic adrenalectomy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Posterior laparoscopic adrenalectomy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 36
Study: 1718250

Group type: EXPERIMENTAL
Intervention: Laser treatment (argon green or krypton red lasers)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Untreated eyes
Number of subjects: 362
Study: 7074317

Group type: EXPERIMENTAL
Intervention: Prophylactic heparinization
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (non-heparinized patients)
Number of subjects: 50
Study: 29953509

Group type: EXPERIMENTAL
Intervention: New onset atrial fibrillation (NOAF)
Number of subjects: 5130
Study: 28850499

Group type: EXPERIMENTAL
Intervention: Isometric activation (ISOM) of deep multifidi muscles
Number of subjects: 24

Group type: COMPARATOR
Intervention: Global activation of paravertebral muscles (GLOB)
Number of subjects: 24
Study: 25913873

Group type: EXPERIMENTAL
Intervention: Elevated lighting systems in classrooms (intervention arm: 178 students)
Number of subjects: 317
Study: 22956062

Group type: EXPERIMENTAL
Intervention: Clinical follow-up (experimental arm)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Complete axillary lymph node dissection (control arm)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Both arms (control and experimental)
Number of subjects: 247
Study: 20572378

Group type: EXPERIMENTAL
Intervention: Generic product of a single oral 8 mg rosiglitazone tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Innovator's product of a single oral 8 mg rosiglitazone tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of generic product to innovator's product
Number of subjects: 24
Study: 17637602

Group type: EXPERIMENTAL
Intervention: Almonds (raw, dry unsalted roasted, natural sliced, roasted salted, honey roasted)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fasted condition
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sliced almonds
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Number of chews and mastication time
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Almond form or flavor
Number of subjects: 24
Study: 15858965

Group type: EXPERIMENTAL
Intervention: Hydrolysed formula (formula A)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional preterm infant formula (formula B)
Number of subjects: 21
Study: 12682308

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg per os twice a day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 11110418

Group type: EXPERIMENTAL
Intervention: Herpes simplex virus thymidine kinase/ganciclovir (HSV‐tk/GCV) gene therapy by direct intracerebral injection of retrovirus (RV) vector producing cells (VPC) during tumor surgery and subsequent systemic administration of GCV
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Herpes simplex virus thymidine kinase/ganciclovir (HSV‐tk/GCV) gene therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (not receiving HSV‐tk/GCV gene therapy)
Number of subjects: 13
Study: 8681594

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 98

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Propofol and Midazolam
Number of subjects: 98
Study: 1922908

Group type: EXPERIMENTAL
Intervention: Frusemide 0.5 mg/kg body weight (Study 1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Frusemide 1.0 mg/kg body weight (Study 2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Frusemide (both studies)
Number of subjects: 14
Study: 6802019

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg)
Number of subjects: 50
Study: 29615172

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with adjunctive mitomycin C
Number of subjects: 60

Group type: COMPARATOR
Intervention: Trabeculectomy without adjunctive mitomycin C
Number of subjects: 60
Study: 25819076

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control
Number of subjects: 124
Study: 24669014

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Induction TPF in cN+ patients with low GDF15 expression
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Induction TPF in cN- patients with high GDF15 expression
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Decreased GDF15 expression in OSCC lines
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Overexpression of GDF15
Number of subjects: 230
Study: 22823552

Group type: EXPERIMENTAL
Intervention: Pharmacist-delivered medication therapy management (MTM) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTM visits scheduled separately from other clinic appointments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provider response to pharmacist recommendations
Number of subjects: 0
Study: 20516309

Group type: EXPERIMENTAL
Intervention: Boston brace worn for more than twelve hours per day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Boston brace worn for fewer than seven hours per day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Boston brace wear (general)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Boston brace wear
Number of subjects: 100
Study: 18544146

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.03 mcg.kg(‐1).min(‐1)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 15813839

Group type: EXPERIMENTAL
Intervention: High-intensity intervention (academic group detailing by a gastroenterologist and reinforcement by pharmacists)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: High-intensity intervention
Number of subjects: 581

Group type: COMPARATOR
Intervention: Low-intensity intervention (guidelines, patient-lists, and toolkit)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 581
Study: 12150231

Group type: EXPERIMENTAL
Intervention: Study 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study 2
Number of subjects: 0
Study: 10468257

Group type: EXPERIMENTAL
Intervention: Pulse contour cardiac output (PCCO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Thermodilution cardiac output (TDCO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Transcardiopulmonary cardiac output (TCPCO)
Number of subjects: 12
Study: 7834970

Group type: EXPERIMENTAL
Intervention: Oxygen therapy (100% humidified at 101/min for 8-10 h prior to ultrasound)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control - no oxygen
Number of subjects: 58
Study: 1972836

Group type: EXPERIMENTAL
Intervention: EMLA 2% cream
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: EMLA 5% cream
Number of subjects: 10
Study: 25075

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acebutolol (300 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol (100 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxprenolol (100 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Timolol (10 mg)
Number of subjects: 10
Study: 31523169

Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao (YB) treatment
Number of subjects: 60
Study: 27990643

Group type: EXPERIMENTAL
Intervention: CN-105 (active treatment)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 48
Study: 26030115

Group type: EXPERIMENTAL
Intervention: Horticultural therapy (HT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nonhorticultural occupational therapy (OT)
Number of subjects: 49
Study: 23343964

Group type: EXPERIMENTAL
Intervention: Transnasal argon plasma coagulation (APC)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Peroral argon plasma coagulation (APC)
Number of subjects: 101
Study: 21865980

Group type: EXPERIMENTAL
Intervention: Ca‐gluconate powder supplementation
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard feeds (Control)
Number of subjects: 99
Study: 18786982

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subtherapeutic CPAP for 4 weeks
Number of subjects: 100
Study: 17004075

Group type: EXPERIMENTAL
Intervention: Internal screw fixation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cast immobilisation
Number of subjects: 47
Study: 15329423

Group type: EXPERIMENTAL
Intervention: CardioWest Total Artificial Heart
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (no artificial heart)
Number of subjects: 116
Study: 11158809

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5% ophthalmic solution
Number of subjects: 104

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 104
Study: 9651141

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 14
Study: 7660237

Group type: EXPERIMENTAL
Intervention: Applied Rehabilitation Concepts system
Number of subjects: 67

Group type: COMPARATOR
Intervention: Dual inclinometry
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Applied Rehabilitation Concepts with improved stabilization techniques
Number of subjects: 67
Study: 2695155

Group type: EXPERIMENTAL
Intervention: 1 microgram/min of sulprostone until delivery
Number of subjects: 85

Group type: COMPARATOR
Intervention: 1500 micrograms of sulprostone in 8 hours followed by another identical course if delivery did not occur within 24 hours
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both regimens (1 microgram/min and 1500 micrograms in 8 hours)
Number of subjects: 85
Study: 187356

Group type: EXPERIMENTAL
Intervention: Clonidine (300 mug)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31220560

Group type: EXPERIMENTAL
Intervention: Bushen capsules (BSC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 60
Study: 28714097

Group type: EXPERIMENTAL
Intervention: Family-based interpersonal psychotherapy (FB-IPT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Family-based health education (FB-HE)
Number of subjects: 29
Study: 25503617

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU) administered twice daily for 1 week
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (48 IU) administered twice daily for 1 week
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (72 IU) administered twice daily for 1 week
Number of subjects: 23

Group type: COMPARATOR
Intervention: Combined oxytocin groups vs placebo
Number of subjects: 23
Study: 22471951

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 0
Study: 21646616

Group type: EXPERIMENTAL
Intervention: Capecitabine with Bevacizumab (CG)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Capecitabine without Bevacizumab (C)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Capecitabine and Bevacizumab (CB)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Capecitabine and Bevacizumab plus Mitomycin (CBM)
Number of subjects: 315
Study: 19351734

Group type: EXPERIMENTAL
Intervention: Arzoxifene 20 mg/d
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 16724896

Group type: EXPERIMENTAL
Intervention: Surgicel (oxidized cellulose) used to seal nephrostomy tract in ten patients.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (ten patients) with nephrostomy tracts left unsealed.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comparison of both groups regarding decrease in hematocrit.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comparison of extravasation from nephrostomy tract between groups.
Number of subjects: 20
Study: 12875313

Group type: EXPERIMENTAL
Intervention: Climbers (n = 9)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Rowers (n = 9)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Leg trained athletes (n = 9)
Number of subjects: 27
Study: 10568909

Group type: EXPERIMENTAL
Intervention: Statistical methods for early stopping in clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triangular test method of early stopping
Number of subjects: 0
Study: 8960814

Group type: EXPERIMENTAL
Intervention: Physical activity and fitness tracking
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Higher fitness level (VO2max)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Inactive lifestyle
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: VO2max levels
Number of subjects: 2
Study: 1756116

Group type: EXPERIMENTAL
Intervention: UVA phototherapy (340‐400 nm)
Number of subjects: 31

Group type: COMPARATOR
Intervention: UVA and UVB phototherapy (300‐400 nm)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High dose of UVA (80‐160 J/cm2; 340‐440 nm) after treatment
Number of subjects: 31
Study: 6187065

Group type: EXPERIMENTAL
Intervention: Disopyramide retard (DR) 2 X 300 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propranolol retard (PR) 1 X 160 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3916850

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 20
Study: 31606753

Group type: EXPERIMENTAL
Intervention: D-fortified sunflower oil (500 IU/30 g)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Unfortified sunflower oil
Number of subjects: 65
Study: 29300708

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (ROP)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Saline (NS)
Number of subjects: 153
Study: 27575992

Group type: EXPERIMENTAL
Intervention: HB-C (home-based computer vergence/accommodative therapy)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: HB-PU (home-based near target push-up therapy)
Number of subjects: 204

Group type: COMPARATOR
Intervention: HB-P (home-based placebo treatment)
Number of subjects: 204